An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).

被引：3
|
作者：
Kabbinavar, Fairooz F.
Zomorodian, Nazy
Rettig, Matthew
Khan, Faraz
Greenwald, Daniel Reif
DiCarlo, Brian
Davidson, Sheldon J.
Patel, Ravindranath
Pandit, Lalita
Chandraratna, Rosh
Sanders, Martin
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Los Angeles, CA 90095 USA
[2] VA Greater Los Angeles Healthcare Syst, Dept Med, West Los Angeles, CA USA
[3] Tanslat Res Oncol US, Los Angeles, CA USA
[4] Translat Oncol Res Int, Santa Maria, CA USA
[5] Lalita Pandit MD Inc, Fountain Valley, CA USA
[6] Therapeut Inc, Santa Ana, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.169
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
169
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC).
    Morris, Michael J.
    Bruce, Justine Yang
    Reyno, Leonard M.
    Anand, Banmeet
    Hartford, Alan
    Jelaca-Maxwell, Kathy
    Lackey, Jacqueline
    Eisenberger, Mario A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] A phase I trial of AEZS-108 in castration- and taxane-resistant prostate cancer
    Liu, Stephen V.
    Schally, Andrew V.
    Dorff, Tanya B.
    Tsao-Wei, Denice
    Groshen, Susan G.
    Hawes, Debra
    Xiong, Shigang
    Quinn, David I.
    Tai, Yu-Chong
    Block, Norman L.
    Engel, Juergen
    Pinski, Jacek K.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] An open-label, phase I/II safety, pharmacokinetic, and proof-of concept study of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (CRPC)
    Fizazi, K.
    Bono, P.
    Jones, R. H.
    Kataja, V.
    James, N.
    Garcia, J.
    Protheroe, A.
    Vuorela, A.
    Mattila, L.
    Mustonen, M. V. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S680 - S680
  • [24] A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer
    Petrylak, D. P.
    Resto-Garces, K.
    Tibyan, M.
    Mohile, S. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Utidelone for heavily pretreated metastatic castration-resistant prostate cancer after failing docetaxel treatment: An open-label, single-arm, phase II trial
    Chen, Meiting
    An, Xin
    Xue, Cong
    Li, Haifeng
    Yang, Wei
    Huang, Riqing
    Peng, Jing
    Tang, Li
    Wang, Jun
    Li, Yonghong
    Shi, Yanxia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS (CRPC)
    Verzoni, E.
    Bajetta, E.
    Giganti, M. O.
    Guadalupi, V.
    Capone, F.
    Donegani, S.
    Nicolai, N.
    Salvioni, R.
    Valdagni, R.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 278 - 278
  • [27] Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
    Chi, Kim N.
    Higano, Celestia S.
    Blumenstein, Brent
    Ferrero, Jean-Marc
    Reeves, James
    Feyerabend, Susan
    Gravis, Gwenaelle
    Merseburger, Axel S.
    Stenzl, Arnulf
    Bergman, Andries M.
    Mukherjee, Som D.
    Zalewski, Pawel
    Saad, Fred
    Jacobs, Cindy
    Gleave, Martin
    de Bono, Johann S.
    LANCET ONCOLOGY, 2017, 18 (04): : 473 - 485
  • [28] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
    Guadalupi, V.
    Giganti, M. O.
    Testa, I.
    Villa, S.
    Nicolai, N.
    Biasoni, D.
    Salvioni, R.
    Valdagni, R.
    Bajetta, E.
    Procopio, G.
    ANTICANCER RESEARCH, 2010, 30 (04) : 1536 - 1536
  • [29] Trial design for metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Fleming, Mark T.
    Hutson, Thomas E.
    Galsky, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3647 - 3648
  • [30] Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD) a multicentre, open-label, phase 2 trial
    Smith, Matthew R.
    Scher, Howard, I
    Sandhu, Shahneen
    Efstathiou, Eleni
    Lara, Primo N.
    Yu, Evan Y.
    George, Daniel J.
    Chi, Kim N.
    Saad, Fred
    Stahl, Olof
    Olmos, David
    Danila, Daniel C.
    Mason, Gary E.
    Espina, Byron M.
    Zhao, Xin
    Urtishak, Karen A.
    Francis, Peter
    Lopez-Gitlitz, Angela
    Fizazi, Karim
    LANCET ONCOLOGY, 2022, 23 (03): : 362 - 373
12345